Trademark: 97486079
Word
MINSPIRE-NA
Status
Dead
Status Code
606
Status Date
Monday, March 18, 2024
Serial Number
97486079
Mark Type
4000
Filing Date
Friday, July 1, 2022
Published for Opposition
Tuesday, June 20, 2023
Abandoned Date
Monday, March 18, 2024

Trademark Owner History
ModernaTx, Inc. - Owner At Publication

Classifications
5 vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological, and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations, all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of pharmaceuticals; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
1 lipid nanoparticles for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, and metabolic disorders; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders
42 Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
M INSPIRE NA

Trademark Events
Mar 18, 2024
Abandonment Notice E-Mailed - No Use Statement Filed
Mar 18, 2024
Abandonment - No Use Statement Filed
Aug 30, 2023
Teas Change Of Correspondence Received
Aug 30, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 30, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 30, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 30, 2023
Teas Change Of Owner Address Received
Aug 15, 2023
Noa E-Mailed - Sou Required From Applicant
Aug 10, 2023
Teas Change Of Correspondence Received
Aug 10, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 10, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 10, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 10, 2023
Teas Change Of Owner Address Received
Jun 20, 2023
Official Gazette Publication Confirmation E-Mailed
Jun 20, 2023
Published For Opposition
May 31, 2023
Notification Of Notice Of Publication E-Mailed
May 11, 2023
Approved For Pub - Principal Register
May 6, 2023
Teas/Email Correspondence Entered
May 5, 2023
Correspondence Received In Law Office
May 5, 2023
Teas Response To Office Action Received
Apr 17, 2023
Notification Of Non-Final Action E-Mailed
Apr 17, 2023
Non-Final Action E-Mailed
Apr 17, 2023
Non-Final Action Written
Apr 17, 2023
Assigned To Examiner
Jul 21, 2022
New Application Office Supplied Data Entered
Jul 5, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24